Dynavax Technologies Stock Forecast, Price & News

-0.11 (-1.22 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.91 million shs
Average Volume4.43 million shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

Dynavax Technologies logo

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

531st out of 2,100 stocks

Pharmaceutical Preparations Industry

255th out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

Is Dynavax Technologies a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Dynavax Technologies?

Wall Street analysts have given Dynavax Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dynavax Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Dynavax Technologies

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The biopharmaceutical company earned $83.34 million during the quarter, compared to analyst estimates of $60.42 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 50.48% and a negative net margin of 51.91%.
View Dynavax Technologies' earnings history

How has Dynavax Technologies' stock been impacted by COVID-19?

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DVAX stock has increased by 190.9% and is now trading at $8.93.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DVAX?

3 brokerages have issued 1 year target prices for Dynavax Technologies' stock. Their forecasts range from $15.00 to $20.00. On average, they anticipate Dynavax Technologies' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 96.0% from the stock's current price.
View analysts' price targets for Dynavax Technologies
or view top-rated stocks among Wall Street analysts.

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the following people:
  • Mr. Ryan Spencer, CEO & Director (Age 43, Pay $859.99k)
  • Mr. David F. Novack, Pres & COO (Age 59, Pay $799.2k)
  • Mr. Michael S. Ostrach, Advisor (Age 69, Pay $721.35k)
  • Dr. Robert Janssen, Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs (Age 67, Pay $725.27k)
  • Ms. Kelly MacDonald, Sr. VP & CFO (Age 37)
  • Mr. Justin Burgess, Principal Accounting Officer & Controller
  • Mr. Jeff P. Coon, Sr. VP of HR & Admin. (Age 58)
  • Ms. Heather Rowe, VP of Investor Relations & Corp. Communications
  • Ms. Meg Smith, VP Sales & Operations
  • Ms. Cecilia Vitug, VP of HR

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies CEO Eddie Gray on Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dynavax Technologies' key competitors?

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (11.00%), BlackRock Inc. (7.47%), Chicago Capital LLC (5.11%), Blair William & Co. IL (1.98%), Geode Capital Management LLC (1.48%) and Rock Springs Capital Management LP (1.45%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David F Novack, Francis Cano, Justin Burgess and Robert Janssen.
View institutional ownership trends for Dynavax Technologies

Which major investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Edmond DE Rothschild Holding S.A., Redmile Group LLC, Credit Suisse AG, Northern Trust Corp, Victory Capital Management Inc., Jackson Square Capital LLC, and Price T Rowe Associates Inc. MD. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, Justin Burgess, and Robert Janssen.
View insider buying and selling activity for Dynavax Technologies
or view top insider-selling stocks.

Which major investors are buying Dynavax Technologies stock?

DVAX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Federated Hermes Inc., D. E. Shaw & Co. Inc., BlackRock Inc., Citigroup Inc., Barclays PLC, Rafferty Asset Management LLC, and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano.
View insider buying and selling activity for Dynavax Technologies
or or view top insider-buying stocks.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $8.93.

How much money does Dynavax Technologies make?

Dynavax Technologies has a market capitalization of $1.02 billion and generates $46.55 million in revenue each year. The biopharmaceutical company earns $-75,240,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Dynavax Technologies have?

Dynavax Technologies employs 245 workers across the globe.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is

Where are Dynavax Technologies' headquarters?

Dynavax Technologies is headquartered at 2100 Powell Street Suite 900, Emeryville CA, 94608.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.